ClinicalTrials.gg
CompletedNCT03404791Updated Feb 4, 2025

A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

A Phase 1 interventional study of TAR-200 in Urinary Bladder Neoplasms, sponsored by Janssen Research & Development, LLC. Completed at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Urinary Bladder Neoplasms by Johnson & Johnson — 2 open to participants now, 5 under way, 2 of them phase 3. Urinary Bladder Neoplasms · Johnson & Johnson.

Enrollment
6th of 10
35 · median 71
Started
2017
the only one that year
Phase 1
5 of 12
none open now
Registered
3rd of 12
by date

Among the 12 studies in Urinary Bladder Neoplasms by Johnson & Johnson, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2017, is one of 5 in phase 1, and was the 3rd registered.

Urinary Bladder Neoplasms

1,801 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

2 of the 12 studies in Urinary Bladder Neoplasms by Johnson & Johnson are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 337 Urinary Bladder Neoplasms studies recruiting now, 257 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Urinary Bladder Neoplasms by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate both the safety and tolerability of up to 4 dosing cycles of TAR-200 for 21 days per dosing cycle in the induction period.

03

Conditions studied

  • Urinary Bladder Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological proof of non- muscle-invasive urothelial cell carcinoma of the bladder
  • Participant must have been as fully resected as possible per the physician's judgment
  • Participants must be deemed unfit for RC due to comorbid conditions with a risk of mortality
  • Participants must refuse or be deemed ineligible for cisplatin-based chemotherapy
  • Participant must refuse or not be eligible for radiotherapy

Exclusion criteria

Exclusion Criteria:

  • Other active
  • Presence of any bladder or urethral anatomic feature that in the opinion of the Investigator may prevent the safe placement, indwelling use, or removal of TAR-200
  • Pyeloureteral tube externalized to the skin (ureteral stent or unilateral nephrostomy tube is allowed)
  • Evidence of bladder perforation during diagnostic cystoscopy
  • Concurrent infections as determined by the treating Investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Participants Ineligible for Radical Cystectomy

    Participants will receive the TAR-200 transuretherally on Day 0 in to the bladder through an Inserter and gradually releases gemcitabine during the 21-day indwelling period before being removed on Day 21 via flexible or rigid cystoscopy. Participants will undergo an 84-day induction period comprised of four consecutive 21-day dosing cycles. Participants may undergo 21 day cycle every 3 months for a maximum of 3 cycles as maintenance (Up to 14 months). Each TAR-200 system will be removed at 21 days after insertion.

    Drug: TAR-200

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability

    An Adverse Event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the intervention under study.

    Time frame: Up to Day 84

Secondary outcomes

  1. Percentage of Participants with Clinical Complete Response (cCR)

    Percentage of Participants with Clinical Complete Response (cCR) will be reported as assessed by cystoscopy, pelvic computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and biopsy (at 12 weeks only, unless clinically indicated).

    Time frame: Up to Day 360

  2. Percentage of Participants with Clinical Partial Response (cPR)

    Percentage of participants with clinical partial response (cPR) will be reported as assessed by cystoscopy, pelvic computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and biopsy (at 12 weeks only, unless clinically indicated).

    Time frame: Up to Day 360

  3. Percentage of Participants with Stable Disease (SD)

    Percentage of participants with stable disease (SD) will be reported as assessed by cystoscopy, pelvic computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and biopsy (at 12 weeks only, unless clinically indicated).

    Time frame: Up to Day 360

  4. Percentage of Participants with Disease Progression

    Percentage of participants with disease progression as assessed by cystoscopy, pelvic computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and biopsy (at 12 weeks only, unless clinically indicated)

    Time frame: Up to Day 360

  5. Symptom Control

    Symptom Control is defined as changes in bladder-related symptoms per the protocol-specified bladder symptom (Urinary frequency, Nocturia, Hematuria and Dysuria/pain) and toxicity grading system (Grade 0-3).

    Time frame: Up to Day 360

  6. Time to Intervention for Symptom Control

    Time to intervention for symptom control, defined as the time from the date of the first TAR-200 insertion to the date of intervention for symptom palliation.

    Time frame: Up to Day 360

  7. Time to Progression

    Time to progression, defined as the time from the date of the first TAR-200 insertion to the date of first occurrence of progression.

    Time frame: Up to Day 360

  8. Percentage of Participants Undergoing Post-treatment Interventions by 3, 6, 9, and 12 Months

    Percentage of participants undergoing post-treatment interventions for the management of local symptoms by 3, 6, 9, and 12 months.

    Time frame: Up to 3, 6, 9, and 12 Months

  9. Percentage of Participants Surviving at 12, 24, and 36 Months

    Percentage of participants surviving at 12, 24, and 36 months compared to all participants.

    Time frame: At 12, 24, and 36 months

07

Study locations

12 sites
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • North Georgia Urology Center
    Dalton, Georgia 30720, United States
  • Chesapeake Urology Research Associates
    Hanover, Maryland 21076, United States
  • Michigan Institute of Urology
    Troy, Michigan 48084, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Urology Associates, PC
    Nashville, Tennessee 37209, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • North Austin Urology
    Austin, Texas 78750, United States
  • Urology of Virginia, PLCC
    Virginia Beach, Virginia 23462, United States
  • Fund. Puigvert
    Barcelona, 08025, Spain
  • Hosp. Univ. 12 de Octubre
    Madrid, 28041, Spain
  • Inst. Valenciano de Oncologia
    Valencia, 46009, Spain
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Dec 2019, 25 months.

Of 80 industry-sponsored phase 1 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 25 months is below that.

Counting every sponsor, half of 145 studies reached it within 43 months; a quarter within 29 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2017
First posted
Jan 19, 2018
StartActual
Nov 20, 2017
Primary completionActual
Dec 23, 2019
CompletionActual
Sep 15, 2022
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03404791
Responsible party
Sponsor
First posted
Jan 19, 2018
Start date
Nov 20, 2017
Primary completion
Dec 23, 2019
Completion
Sep 15, 2022
Last update
Feb 4, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine-Releasing Intravesical System

Start the discussion